Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news claude_news gdelt_news wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This resolves on the 4-year average (2025–2028) of US measles cases, i.e. total ≥20,000 cases — far above 2025's record-since-1992 count (~2,000–2,900). The key research is the confirmed 2025 CDC total, the trajectory of 2026 outbreaks, MMR vaccination coverage declines, and whether the US lost elimination status, plus the Kalshi market price as anchor.

# Current state Resolution requires the average annual measles case count for 2025–2028 to be ≥5,000 (i.e., cumulative ≥20,000 cases over 4 years). CDC's final 2025 total was 2,289 confirmed cases; 2026 YTD (as of early Aug 2026) already exceeds all of 2025 at ~2,465–2,500+ cases and is the worst year since 1991/92. Cumulative Trump-era total (Jan 2025–late July 2026, ~19 months) is ~4,660 cases — roughly on pace for only ~2,900–3,000/year, well below the ~5,000/year run-rate needed. # Timeline of key events - 2025-01 to 2025-08: Southwest US outbreak (Texas/Mennonite communities, Gaines County epicenter) — largest single driver of 2025 total; declared over 2025-08-18 (confirmed, Wikipedia/CDC). - 2025 (full year): CDC final tally 2,289 confirmed cases across 45 jurisdictions, 48-49 outbreaks; 90% outbreak-associated; 11% hospitalized, 3 deaths (confirmed, CDC/claude_news). Highest since 1991/92. - 2025-11: Canada loses measles elimination status (confirmed, claude_news). - 2026-01-05: HHS/RFK Jr. announces overhaul of childhood vaccine schedule, cutting universal recommendations from 17 to 11 (confirmed, The Conversation). - 2026-03-16: Federal court (Judge Murphy) stays/blocks CDC's schedule reduction, ruling CDC exceeded authority by bypassing ACIP (confirmed, AJMC/AOL). - 2026-06-18 to 07-26: US case count climbs from 2,104 (41 states) → 2,170 → 2,318 → 2,465, surpassing full-year 2025 total by early summer; South Carolina/Spartanburg, Utah, Virginia, Pennsylvania named as major ongoing outbreak sites (confirmed, CIDRAP/Medical Daily/NBC). - 2026-08-03: RFK Jr. publicly urges measles vaccination amid ongoing outbreak (reported, ABC). - 2026-11 (upcoming): PAHO scheduled to review US transmission data; US widely expected to lose elimination status held since 2000 (reported/anticipated, multiple outlets). # Event Will the average annual US measles case count over 2025–2028 (Trump's term) be at least 5,000? # Outcomes to forecast - Yes (average ≥5,000/yr, i.e., cumulative ≥20,000 over 4 years) - No (average <5,000/yr) # Kalshi market anchor Current YES price: **34%** (KXAVGMEASLESDJT-29-5000). 7-day change +1pt, 30-day change +1pt. Price range over 45 days: 28%–36%. Average daily volume: 173 contracts (thin but active). Market has drifted modestly upward but remains well below 50%. # Sub-question answers 1. **2025 CDC total vs prior years** — CDC final 2025 total: 2,289 confirmed cases (some sources cite 2,144 or 2,255; reconciled to CDC's official 2,289), the highest since 1991/92 — more than double 2019 (1,274) and 2014 (667). [CDC, claude_news, Wikipedia] 2. **2026 YTD pace** — As of ~Aug 7, 2026, ~2,465 cases confirmed, already exceeding all of 2025 by ~early July; pace is accelerating vs 2025 but total Trump-era (19 months) sum is only ~4,660, implying ~2,900-3,000/yr average pace, not ~5,000+. [CIDRAP, claude_news] 3. **Elimination status** — Not yet formally lost; PAHO review expected November 2026, widely anticipated the US will lose the status held since 2000 (Canada already lost it Nov 2025). Losing status signals endemic transmission risk but doesn't mechanically guarantee case counts ≥5,000/yr. [claude_news, Wikipedia] 4. **MMR coverage trend** — Kindergarten MMR coverage fell from 95.2% (2019-20) to 92.5% (2024-25), ~286,000 kindergartners under-vaccinated; below the ~92-95% herd-immunity threshold cited in vaccine literature. [claude_news, Wikipedia/measles vaccine] 5. **Base rate / required trajectory** — No year 1993–2024 (post-elimination) exceeded 2019's 1,274 until 2025's 2,289. Reaching a 4-yr avg ≥5,000 requires cumulative ≥20,000 cases 2025-28, i.e., ~17,100 across 2026-28 (≈5,700/yr), requiring sustained ~38%/yr compounding growth from 2025 — far beyond any historical post-elimination year. [code_execution] 6. **Federal policy risk factors** — Jan 2026 HHS/RFK Jr. vaccine-schedule cut (17→11 vaccines) could erode MMR uptake further, but a federal court stayed the change (March 2026), creating ongoing legal/policy uncertainty rather than a clear accelerant. [claude_news] # Key facts 1. [CDC/Wikipedia] 2025 final: 2,289 cases, 48-49 outbreaks, 3 deaths. 2. [CIDRAP/claude_news] 2026 YTD (~Aug) ~2,465-2,500 cases, already above 2025 full-year total — 35-year high. 3. [claude_news] Trump-era cumulative (Jan 2025–late Jul 2026): ~4,660 cases. 4. [claude_news] Kindergarten MMR coverage: 92.5% (2024-25) vs 95.2% (2019-20). 5. [code_execution] Need ~20,000 cumulative cases 2025-2028 (~5,700/yr in 2026-28) to hit threshold — requires ~38%/yr sustained growth, unprecedented historically. 6. [AJMC] March 2026 court stay blocks RFK Jr.'s vaccine-schedule cuts, adding policy uncertainty. # Cross-market signals - Kalshi related: only this market itself found (34%); no distinct sub-markets for elimination-status or annual thresholds. - Polymarket: no measles/vaccine markets found. - Sportsbook implied: N/A (not applicable to this event type). # Analyst opinions and speculation - Stanford/JAMA (Kiang et al.) long-run model: under current vaccination trends, ~34,000/yr average over 25 years if endemicity re-establishes (83% of simulations, mean 20.9 yrs to endemicity) — but this is a 25-year horizon, not directly 2025-28. - Yale/medRxiv near-term model: 1%/yr MMR decline scenario projects 2030 cases ~17,232 (sevenfold rise from 2025) — suggests threshold-level annual counts plausible by end of decade but likely after 2028. - code_execution Monte Carlo (aggressive priors: median 1.3x/yr growth): ~46% probability of hitting ≥5,000 avg; with conservative priors (1.1x/yr), <20%. # Directional lean per outcome - **Yes**: Elimination status likely lost (Nov 2026 review), record 2026 outbreaks, declining MMR coverage, HHS policy turmoil, and accelerating outbreak-associated case share (94% in 2026) all support upward momentum. - **No**: Actual pace (~2,900-4,660 cumulative over 19 months) is far below the ~5,700/yr needed for 2026-28; no historical post-elimination year has approached 5,000; court has blocked the most aggressive vaccine-schedule rollback; most credible near-term models (Yale) put 2030 cases at ~17,000 — a single year, not sustained multi-year average. # Gaps / unknowns - No confirmed 2027/2028 case data (outside current knowledge horizon). - Uncertain whether US formally loses elimination status in Nov 2026 and what practical effect that has on case trajectory. - Legal fate of HHS vaccine schedule changes unresolved, affecting future MMR coverage trends. - Data discrepancies in 2025 totals (2,144 vs 2,255 vs 2,289) unresolved — CDC's own page cited as authoritative (2,289). # Calibration anchors - Kalshi current YES price: 34% (anchor). - Historical precedent: no year 1993-2024 exceeded 1,274 cases (2019); 2025's 2,289 is already a 34-year record, yet still <50% of the ~4,600/yr pace implied by current cumulative total, and far below the ~5,700/yr needed for 2026-28.

1. Both forecasters anchor tightly on the arithmetic pace argument but underweight the Monte Carlo evidence in the brief itself: with "aggressive priors" the model gives ~46% probability of hitting the threshold, which is far above both forecasts' 24%/30% — neither addresses why they're discounting this scenario so heavily versus the conservative-prior (<20%) case. 2. Neither forecast explicitly grapples with nonlinear outbreak dynamics — measles spread is highly exponential/threshold-driven once elimination status is lost and pockets of unvaccinated populations reach critical mass (per the Kiang/Stanford model showing 83% of simulations reaching endemicity), so a simple linear extrapolation from 19 months of data may understate tail risk of a genuine outbreak cascade in 2027-28. 3. Both treat the Nov 2026 elimination-status loss as a minor signal ("doesn't mechanically guarantee case counts") but don't quantify how much larger outbreaks tend to be once a country transitions to endemic transmission (e.g., comparing to what happened post-elimination-loss in other countries), leaving a potentially underweighted accelerant. 4. Neither forecast considers seasonality/reporting lag risk — 2026 YTD data through early August likely undercounts the full-year total given outbreaks often peak in fall/winter (as seen with the 2025 Southwest outbreak extending through August), so the "~2,900-3,000/yr" implied pace may be a lower bound rather than a stable rate. 5. Both forecasters land close to each other (24% vs 30%) and both below the Kalshi price (34%), but neither explains why the market — which has drifted up modestly over 30/7 days — might be pricing in information (e.g., anticipation of the Nov PAHO review or ongoing outbreak trajectories) that their point estimates discount; this convergence without engaging alternative explanations for the market's persistence above their fair-value estimates warrants more scrutiny. 6. Both give substantial rhetorical weight to the court stay blocking the vaccine-schedule rollback, but the brief notes this is "ongoing legal/policy uncertainty" — an appeal or reversal could still restore the accelerant within the 2026-2028 window, a tail scenario neither forecast quantifies separately.

27% (medium confidence)

Yes: 27% No: 73%

The threshold requires ~20,000 cumulative cases in 2025–2028; with 2,289 in 2025 and ~2,465 through early August 2026 (likely finishing ~3,300–4,000 with fall/winter seasonality and reporting lag), 2027 and 2028 would each need roughly 7,000 cases — about double 2026 and ~5x the pre-2025 record. That is achievable only under a genuine endemic-transmission cascade, which the Kiang/Stanford and Yale models suggest is plausible but typically materializes after 2028. The critique's points on nonlinear outbreak dynamics, seasonality undercount, likely Nov 2026 loss of elimination status, and possible reversal of the court stay legitimately fatten the upper tail, so I do not sit as far below the market as the two forecasters. I settle just below the 34% Kalshi anchor, reflecting that the arithmetic burden is genuinely steep while acknowledging the market may be pricing real acceleration risk the pace extrapolation misses.

Total pipeline time: 267.0s